Preprint Brief Report Version 1 Preserved in Portico This version is not peer-reviewed

Brief Report: Rapid Clinical Recovery from Severe COVID-19 with High Dose Famotidine and High Dose Celecoxib Adjuvant Therapy

Version 1 : Received: 20 August 2020 / Approved: 24 August 2020 / Online: 24 August 2020 (09:46:15 CEST)

How to cite: tomera, K.; kittah, J. Brief Report: Rapid Clinical Recovery from Severe COVID-19 with High Dose Famotidine and High Dose Celecoxib Adjuvant Therapy. Preprints 2020, 2020080519 (doi: 10.20944/preprints202008.0519.v1). tomera, K.; kittah, J. Brief Report: Rapid Clinical Recovery from Severe COVID-19 with High Dose Famotidine and High Dose Celecoxib Adjuvant Therapy. Preprints 2020, 2020080519 (doi: 10.20944/preprints202008.0519.v1).

Abstract

Celecoxib as adjuvant therapy has been shown in a small randomized trial for Covid-19 to prevent clinical deterioration and rapidly improve thoracic computerized axial tomography (CT-chest)1. Multiple descriptive trials of high dose famotidine (both inpatient and outpatient) have demonstrated clinical response2,3,4. We describe the rapid clinical responses after increasing the celecoxib dosage to 400mg bid with high dose famotidine 80mg qid in both a critical inpatient who on baseline required 40 liters per minute high flow nasal insufflation and an outpatient who declined admission but had critical Covid-19 biomarkers.

Subject Areas

SARS-CoV-2, COVID-19, Acute Respiratory Distress Syndrome, ARDS, Famotidine, Celecoxib

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our diversity statement.

Leave a public comment
Send a private comment to the author(s)
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.